Shanghai Fosun Pharmaceutical (Group) (SHA:600196, HKG:2196) unit Shanghai Fosun Pharmaceutical Industrial Development obtained clinical trial approval for FXB0871 from China's National Medical Products Administration.
The pharmaceutical firm aims to study the drug for the treatment of locally advanced or metastatic solid tumors.
The company will begin the study once conditions are met.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments